Convection-Enhanced Delivery of Nanoliposomal Irinotecan for Recurrent Glioblastoma or High-Grade Glioma

Article
Conference|Society for NeuroOncology Annual Meeting

Nicholas Butowski, MD, discusses a phase I study of convection-enhanced delivery of nanoliposomal irinotecan (MM-398) for the treatment of recurrent glioblastoma or recurrent high-grade glioma.

Clinical Pearls

Nicholas Butowski, MD, associate professor, University of California, San Francisco, neuro-oncologist, UCSF Medical Center, discusses a phase I study of convection-enhanced delivery of nanoliposomal irinotecan (MM-398) for the treatment of recurrent glioblastoma or recurrent high-grade glioma.

  • 1-3 catheters co-deliver liposomal-irinotecan and gadolinium into a patient’s tumor.
  • Gadolinium is used so that imaging can be done in real-time.
  • This process is unique because it bypasses systemic toxicity and ensures that the drug is administered properly.

<<<

View more from the 2014 SNO meeting

Recent Videos
Related Content
Real-World CAR T-Cell Therapy Outcomes in DLBCL Reveal Challenges and Disparities

Real-World CAR T-Cell Therapy Outcomes in DLBCL Reveal Challenges and Disparities

Kristie L. Kahl
November 15th 2024
Article

Read More

Recommendations for Treating Central Nervous System Cancers

Recommendations for Treating Central Nervous System Cancers

Nichole Tucker;Craig Horbinski, MD, PhD
July 14th 2023
Podcast

In season 4, episode 10 of Targeted Talks, Craig Horbinski, MD, PhD, reviews the clinical practice guidelines for central nervous system cancers.

Listen

Advancements in Follicular Lymphoma Treatment With Targeted Therapies

Advancements in Follicular Lymphoma Treatment With Targeted Therapies

Morgan Bayer
November 14th 2024
Article

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.

Read More

MB-108 Gains FDA Orphan Drug Status for Malignant Glioma Treatment

MB-108 Gains FDA Orphan Drug Status for Malignant Glioma Treatment

Jordyn Sava
November 8th 2024
Article

MB-108 shows activity and is well tolerated in recurrent glioblastoma, with preclinical data supporting its combination with MB-101 CAR T-cell therapy for improved outcomes.

Read More

FDA Grants Priority Review for TLX101-CDx PET Imaging Agent in Glioma

FDA Grants Priority Review for TLX101-CDx PET Imaging Agent in Glioma

Jordyn Sava
October 24th 2024
Article

The FDA accepted the new drug application for TLX101-CDx and granted priority review to the agent in glioma.

Read More

FDA Approves Companion Diagnostic for Vorasidenib in IDH-Mutant Glioma

FDA Approves Companion Diagnostic for Vorasidenib in IDH-Mutant Glioma

Jordyn Sava
October 21st 2024
Article

The FDA has approved the Ion Torrent Oncomine Dx Target Test as a companion diagnostic to identify patients eligible for treatment with vorasidenib.

Read More